Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Our vision is to be a world-class commercial biotechnology company. We believe that we can achieve this with an approach of focused excellence in everything that we do-in working efficiently, in making data-driven decisions quickly, and in advancing promising compounds rapidly. Already, we have built one of the most impressive oncology development pipelines in the biotechnology and pharmaceutical industries.
More >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.13 (3.63%)
Data as of 04/23/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
04/21/14Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014Printer Friendly Version
03/25/14Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate CancerPrinter Friendly Version
03/25/14Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid CarcinomaPrinter Friendly Version
02/26/14Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care ConferencePrinter Friendly Version
Upcoming EventsMore >>
Q1 2014 Financial Results and Business Update Conference Call
Thursday, May 1, 2014 2:00 p.m. PT
Add to Calendar Add Q1 2014 Financial Results and Business Update Conference Call to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.